Bupivacaine 0.25-0.5% — Competitive Intelligence Brief

Bupivacaine 0.25-0.5% (Bupivacaine 0.25-0.5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesiology.

phase 2 Local anesthetic Voltage-gated sodium channels Anesthesiology Small molecule

Target snapshot

Bupivacaine 0.25-0.5% (Bupivacaine 0.25-0.5%) — Rabin Medical Center. Bupivacaine is a local anesthetic that blocks nerve impulses, preventing pain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine 0.25-0.5% TARGET	Bupivacaine 0.25-0.5%	Rabin Medical Center	phase 2	Local anesthetic	Voltage-gated sodium channels
Bupivacaine-adrenaline	Bupivacaine-adrenaline	University of Aarhus	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component)
Permethrin Cream, 5%	Permethrin Cream, 5%	Mayne Pharma International Pty Ltd	marketed	Synthetic pyrethroid insecticide	Voltage-gated sodium channels (arthropod nervous system)
Dexamethasone+ Bupivacaine	Dexamethasone+ Bupivacaine	Ain Shams University	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine)
Bupivacain/levobupivacaine	Bupivacain/levobupivacaine	University Hospital, Basel, Switzerland	marketed	Local anesthetic	Voltage-gated sodium channels
Suzetrigine (SUZ)	Suzetrigine (SUZ)	Vertex Pharmaceuticals Incorporated	marketed	Selective sodium channel inhibitor	Voltage-gated sodium channels (Nav)
All registered antiepileptic drugs	All registered antiepileptic drugs	UMC Utrecht	marketed	Antiepileptic drugs (heterogeneous class)	Multiple targets including voltage-gated sodium channels, GABA receptors, calcium channels, SV2A, and others depending on specific agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class